Document:

EX-10.63

 Exhibit 10.63 
 DaVita HealthCare Partners Inc. 
 Cash Performance Award Agreement

 under the 
 DaVita Inc. 2011 Incentive Award Plan 
 and Long-Term Incentive Program

 Primary Terms 
  

			
	Grantee:	  	Sample Example
		
	Teammate Number:	  	123456
		
	Address:	  	1234 Any Street
		  	Apt. # A
		  	Any Town, US 12345
		
	Grant Date:	  	
		
	Performance Period:	  	[xxx] -year period commencing [START DATE] and ending [END DATE]
		
	Target Award Value:	  	[$xx.x]
		
	Plan Name:	  	2011 Incentive Award Plan
		
	Plan ID:	  	CLTI
		
	Vesting Schedule:	  	[VESTING DATES]

 The terms set forth above, together with the terms and conditions attached, constitute one
agreement. 
 Note: Please mark and initial any correction to the Name, Teammate number and/or Address shown on this page
before returning a signed copy of this agreement to the People Services Department. 

  
 1 

 This Cash Performance Award Agreement (“Agreement”) is dated as of
                     (“Grant Date”) by and between DaVita HealthCare Partners Inc., a Delaware corporation (“Company”) and
Sample Example (“Grantee”) pursuant to the DaVita Inc. 2011 Incentive Award Plan (“Plan”). Capitalized terms that are used but not defined in this document shall have the meanings set forth in the Plan. 

 

	 	1.	Grant of Cash Performance Award. 

 The Company hereby grants a performance award to the Grantee, subject to the terms and conditions herein. This performance award is a cash-settled award with a target value of [$xx.x] (“Target
Value”), the actual gross amount and payment of which (“Payout Amount”) is subject to the performance, vesting and other requirements described below (“Cash Performance Award”). 

 

	 	2.	Terms of Cash Performance Award. 

 (a) The Cash Performance Award will vest on [VESTING DATE] and become payable following the end of the [xxx] -year period commencing on [START DATE] and ending on [END DATE] (“Performance
Period”). 
 (b) The Cash Performance Award will be earned only if the following performance goals are achieved as
applied over the entire Performance Period: 
 (1) [xxx%] based on operating income for the Dialysis &
Related Lab Services operating segment, as presented in the Company’s annual financial statements filed with the Securities and Exchange Commission for the Company’s fiscal year ended [YEAR END DATE] (the “Dialysis Segment”),
[SUBJECT TO SUCH ADJUSTMENTS AS SET FORTH BY THE COMMITTEE]: 
 (operating income for the Dialysis Segment adjusted as described above, the
“Adjusted Dialysis & Lab OI”) of [$xx.x million]. The performance goal described in this subsection 2(b)(1) shall be referred to as the “OI Performance Metric” and such portion of the Target Value dependent on the OI
Performance Metric referred to as the “OI Target Value.” 
 The portion of the Payout Amount attributable to the OI
Performance Metric shall be determined by multiplying the OI Target Value by the Percentage of OI Target Value Earned that corresponds to the level of achievement against the OI Performance Metric during the Performance Period, as described in the
table below: 
  

					
	 [xxxx] Adjusted Dialysis & Lab OI ($ in millions)
	  	Percentage of OI Target Value Earned	 
	 >= $xx.x
	  	 	xxx	% 
	       $ xx.x
	  	 	xxx	% 
	       $ xx.x
	  	 	xxx	% 
	       $ xx.x
	  	 	xxx	% 
	       $ xx.x
	  	 	xxx	% 
	     <$ xx.x
	  	 	xxx	% 

 The Percent of OI Target Value Earned is interpolated for performance between the points indicated in the table above on
a straight-line basis. 
 Notwithstanding the foregoing, if Adjusted Dialysis & Lab OI is greater than [$xx.x million]
and up to [$xx.x million] (the “Exceptional Performance Range”), an incremental percentage of the Dialysis & Lab OI Target Value ranging from [xxx%] to [xxx%], interpolated based on achievement within the Exceptional Performance
Range, shall be added to a pool (“Exceptional Performance Pool”). Amounts in the Exceptional 

  
 2 

 
Performance Pool will increase the Payout Amount under the Cash Performance Award by such amount and to such specific Grantees as the Company shall determine in its sole discretion, provided that
all such Exceptional Performance Pool amounts shall only increase the Payout Amount of Grantees eligible to receive a Cash Performance Award tied to the OI Performance Metric. Nothing in this Section 2(b)(1) shall be an assurance that
Grantee’s Payout Amount under this Award will be increased by any such payouts from the Exceptional Performance Pool. 

[Only if applicable] (2) [xxx%] based on [OTHER PERFORMANCE
GOALS]. 
 The performance goals described in this Section 2(b) shall collectively be referred to as the “Performance
Metric.” 
 (c) The total Payout Amount under this Cash Performance Award shall be equal to the sum of the amount(s)
payable, if any, pursuant to Section 2(b)(1) [and, if applicable, Section 2(b)(2)] of this Agreement. 

(d) Payment of the Payout Amount earned under the Cash Performance Award will be subject to and based upon the level of achievement of
the performance conditions described in this Section 2, as determined by the Company in its sole discretion. 
  

	 	3.	Payment of Cash Performance Awards. 

 (a) Except as otherwise provided herein, any Cash Performance Award payable pursuant to this Agreement is subject to the condition that the Grantee remain employed by the Company through the vesting date.
If the Grantee’s employment is voluntarily or involuntarily terminated for any reason, with or without cause, prior to the vesting date, the Grantee’s Cash Performance Award granted hereunder, irrespective of the extent to which any
achievement has been made against the Performance Metric, will be immediately forfeited in its entirety. 
 (b) Subject to the
provisions of this Section 3, following the end of the Performance Period, the Company will pay to the Grantee the amount of Cash Performance Award earned by the Grantee in a single lump sum cash payment, net of applicable withholding taxes.
Such payment will be made as soon as reasonably practicable following the Company’s determination and certification of the level of performance achievement. 
 (c) If the Grantee is transferred between business units for which the structure and blend of Plan awards or Cash Performance Awards and Performance Metrics differ at any time prior to the end of the
Performance Period, the Company shall have the right in its sole discretion to (i) continue the Cash Performance Award subject to the same Performance Metric provided in Section 2(b); (ii) amend this Agreement in accordance with
Section 7 to make appropriate adjustments to the terms of the Cash Performance Award based on the circumstances of the transfer; or (iii) terminate the Cash Performance Award, in each case as the Company deems appropriate. 

(d) No payment will be made with respect to the Cash Performance Award unless and until the Company (via the Committee as required) has
certified, by resolution or other appropriate action in writing, that the applicable level of achievement relative to the Performance Metric has been accurately determined. The Company shall not have the discretion to pay any amount of Cash
Performance Award if the threshold level of performance is not achieved or to pay an amount of Cash Performance Award in excess of the amount provided in Section 2 above for the applicable level of achievement relative to the Performance
Metric. 
  

	 	4.	Clawback Provision. 

Notwithstanding any other provision in this Agreement to the contrary, the Grantee shall be subject to the written policies of the
Company’s Board of Directors applicable to Company executives, including without limitation any Board policy relating to recoupment or “clawback” of compensation arising from payments such as those made under this Cash Performance
Award, as they exist from time to time during the Grantee’s employment by the Company and thereafter. 

  
 3 

	 	5.	Assignments. 

(a) This Cash Performance Award is payable only to the Grantee during the Grantee’s lifetime, provided that in the
event of the death of the Grantee after vesting of this Cash Performance Award but prior to any payments hereunder, this Cash Performance Award may be payable to the Grantee’s executor, heirs or administrator to whom amounts payable under this
Cash Performance Award may have been assigned or transferred as provided in subsection (b) below. 
 (b) The rights of the
Grantee under this Cash Performance Award may not be assigned or transferred except by will or by the laws of descent and distribution. 
  

	 	6.	Interpretation of Cash Performance Award. 

 (a) This Cash Performance Award is granted under the provisions of the Plan and shall be interpreted in a manner consistent with it. 

(b) Any provision in this Agreement inconsistent with the Plan shall be superseded and governed by the Plan. 

(c) For all purposes under this Agreement, and except as otherwise provided in Section 3(c) of this Agreement, employment by the
Company shall include employment by the Company or any subsidiary thereof. 
  

	 	7.	Amendments. 

 (a)
Except as otherwise provided herein, this Agreement may be amended at any time with the consent of the Company and the Grantee. 

(b) If there is a meaningful reduction, determined in the Company’s sole discretion, in both the Grantee’s duties and
responsibilities and the level of the Grantee’s regular cash compensation for an extended or indefinite period of time, the Company reserves the right to unilaterally revoke some or all of the unvested Cash Performance Award. 

(c) Notwithstanding the foregoing subsections (a) and (b), no amendment or termination of the Plan or this Agreement may adversely
affect in any material respect the rights of the Grantee to the payment of a Cash Performance Award that has been earned as a result of its vesting and having been approved by the Committee under Section 5.5 of the Plan, and a determination and
certification under Section 3 of this Agreement having been made, without such Grantee’s consent. 
  

	 	8.	Tax Withholding.  

The Company will have the power and the right to deduct or withhold, or require the Grantee to remit to the Company, an amount sufficient
to satisfy federal, state, and local taxes, as required by law or regulation to be paid or withheld with respect to any taxable event arising as a result of this Agreement. Notwithstanding the foregoing, in the event the Company does not so deduct
or withhold or require the Grantee to remit such amounts, or the Grantee fails to remit such amounts to the Company if requested to do so, the Grantee shall continue to be responsible for the payment of such taxes, plus any interest and penalties
levied thereon until paid, and agrees to indemnify and hold harmless the Company from and against all such tax liability. 

  
 4 

	 	9.	Section 409A. 

The Cash Performance Award is intended to be exempt from the requirements of Section 409A of the Code pursuant to the short-term
deferral exemption with respect to amounts subject thereto and shall be interpreted and construed in a manner consistent with that intent. If any provision of this Agreement or the Plan causes the Cash Performance Award to become subject to
Section 409A of the Code and the Cash Performance Award does not satisfy the requirements of Section 409A of the Code, or could otherwise cause the Grantee to recognize income or be subject to the interest and penalties under section 409A
of the Code, then that provision shall have no effect or, to the extent practicable, the Company may modify the provision to maintain the original intent without violating the requirements of Section 409A of the Code. 

 

	 	10.	Non-Competition/Non-Solicitation/Non-Disclosure. 

 [Subparagraph (a) applies to Grantees outside of California only.] (a) Non-Competition. The Grantee acknowledges and recognizes the highly competitive nature of the business
of the Company and accordingly agrees that while Grantee is an employee of the Company and for the [one year for VPs/6 months for Directors/3 months for managers] period following termination of such relationship for any reason
(whether voluntary or involuntary) (the “Restricted Period”), the Grantee shall not, as an employee, independent contractor, consultant, or in any other form, prepare to provide or provide any of the same or similar services that Grantee
performed during his/her employment with (or service to) Company for any other individual, partnership, limited liability company, corporation, independent practice association, management services organization, or any other entity (collectively,
“Person”) that competes in any way with the area of business of the Company, or any of its subsidiaries or affiliates, in which Grantee worked and/or performed services. For purposes of the above, preparing to provide any of the same or
similar services includes, but is not limited to, planning with any Person on how best to compete with Company or any of its subsidiaries or affiliates, or discussing Company’s, or any of its subsidiaries’ or affiliates’ business
plans or strategies with any Person. 
 The Grantee further agrees that during Restricted Period, Grantee shall not own, manage,
control, operate, invest in, acquire an interest in, or otherwise engage in, act for, or act on behalf of any Person (other than Company and its subsidiaries and affiliates) engaged in any activity that Grantee was responsible for during
Grantee’s employment with Company where such activity is similar to or competitive with the activities carried on by Company or any of its subsidiaries or affiliates. 
 The Grantee acknowledges that during the Restricted Period, the Grantee may be exposed to confidential information and/or trade secrets relating to business areas of the Company or any of its
subsidiaries or affiliates that are different from and in addition to the areas in which Grantee primarily works for Company (the “Additional Protected Areas of Business”). As a result, the Grantee agrees he/she shall not own, manage,
control, operate, invest in, acquire an interest in, or otherwise act for, act on behalf, or provide the same or similar services to, any Person that engages in the Additional Protected Areas of Business. 

The Grantee acknowledges and agrees that the geographical limitations and duration of this covenant not to compete are reasonable.

 To the extent that the provisions of this Section 10(a) conflict with any other agreement signed by Grantee relating to
non-competition, the provisions that are most protective of the Company’s, and any of its subsidiaries’ or affiliates’, interests shall govern. 
 (b) Non-Solicitation. Grantee agrees that during the term of his/her employment and/or service to Company or any of its subsidiaries or affiliates and for the one-year period following the
termination of his/her employment and/or service for any reason (whether voluntary or involuntary), Grantee shall not (i) solicit any of Company’s or any of its subsidiaries’ or affiliates’ employees to work for any Person,
(ii) hire any of Company’s, or any of its subsidiaries’ or affiliates’, employees to work (as an employee or an independent contractor) for any Person, (iii) take any action that may reasonably result in any of
Company’s, or any of its subsidiaries’ or affiliates’, employees going to work (as an employee or an independent contractor) for any Person, (iv) induce 

  
 5 

 
any patient or customer of Company, or any of its subsidiaries or affiliates, either individually or collectively, to patronize any competing business; (v) request or advise any patient,
customer, or supplier of Company, or any of its subsidiaries or affiliates, to withdraw, curtail, or cancel such person’s business with Company, or any of its subsidiaries or affiliates; (vi) enter into any contract the purpose or result
of which would benefit Grantee if any patient or customer of Company, or any of its subsidiaries or affiliates, were to withdraw, curtail, or cancel such person’s business with Company, or any of its subsidiaries or affiliates;
(vii) solicit, induce, or encourage any physician (or former physician) affiliated with Company, or any of its subsidiaries or affiliates, or induce or encourage any other person under contract with Company, or any of its subsidiaries or
affiliates, to curtail or terminate such person’s affiliation or contractual relationship with Company, or any of its subsidiaries or affiliates; or (viii) disclose to any Person the names or addresses of any patient or customer of
Company, or any of its subsidiaries or affiliates. 
 (c) Non-Disclosure. In addition, Grantee agrees not to disclose or
use for his or her own benefit or purposes or for the benefit or purposes of any Person other than the Company and any of its subsidiaries or affiliates, any trade secrets, information, data, or other confidential information relating to customers,
development, programs, costs, marketing, trading, investment, sales activities, promotion, credit and financial data, financing methods, plans, or the business and affairs of the Company or any of its subsidiaries or affiliates
(“Information”); provided, however, the foregoing shall not apply to (i) Information which is not unique to the Company or any of its subsidiaries or affiliates, or (ii) Information which is generally known to the industry or the
public other than as a result of the Grantee’s breach of this covenant, or (iii) disclosure that is required by any applicable law, rule or regulation. If Grantee receives such a request to produce Information in his or her possession,
Grantee shall provide the Company reasonable advance notice, in writing, prior to producing said Information, so as to give the Company reasonable time to object to Grantee producing said Information. Grantee also agrees that Grantee will not become
employed by or enter into service with any Person other than the Company and any of its subsidiaries or affiliates in which Grantee will be obligated to disclose or use any Information, or where such disclosure would be inevitable because of the
nature of the position. 
 (d) If, at any time within (a) the Performance Period of this Cash Performance Award, or
(b) one (1) year after termination of Grantee’s employment with the Company, or any of its subsidiaries or affiliates, for any reason (whether voluntary or involuntary), whichever is the latest, Grantee (i) breaches the
non-competition provision of Section 10(a), (ii) breaches the non-solicitation provision of Section 10(b), (iii) breaches the non-disclosure provision of Section 10(c), (iv) is convicted of a felony, (v) has been
adjudicated by a court of competent jurisdiction of having committed an act of fraud or dishonesty resulting or intending to result directly or indirectly in personal enrichment at the expense of the Company or any of its subsidiaries or affiliates,
or (vi) is excluded from participating in any federal health care program, then (1) this Cash Performance Award shall terminate effective on the date on which Grantee enters into such activity and (2) the Company may seek temporary,
preliminary, and permanent injunctive relief to prevent any actual or threatened breach or continuation of any breach of this Agreement without the necessity of proving actual damages or posting a bond or other security (which Grantee hereby agrees
to) and/or an order requiring Grantee to repay the Company any amount previously paid to Grantee under this Cash Performance Award. 
  

	 	11.	Employment. 

Nothing in this Agreement will interfere with or limit in any way the right of the Company to terminate the Grantee’s employment at
any time, nor confer upon the Grantee any right to continue in the employ of the Company, nor be deemed a waiver or modification of any agreement between the Grantee and the Company. 

 

	 	12.	Miscellaneous. 

(a) This Agreement and the rights of the Grantee hereunder are subject to all the terms and conditions of the Plan, as the same may be
amended from time to time, as well as to such rules and regulations as the Committee may adopt for administration of the Plan. It is expressly understood by the Grantee that the Committee is authorized to administer, construe, and make all
determinations necessary or appropriate to the administration of the Plan and this Agreement, all of which shall be binding upon the Grantee. 

  
 6 

 (b) The parties hereto acknowledge that there will be no adequate remedy at law for a
violation of any of the provisions of this Agreement and that, in addition to any other remedies which may be available, all the provisions of this Agreement shall be specifically enforceable in accordance with their respective terms. 

(c) The invalidity or unenforceability of any provision of this Agreement in any jurisdiction shall not affect the validity or
enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability of this Agreement, including that provision, in any other jurisdiction. If any provision of this Agreement is held unlawful or unenforceable in
any respect, such provision shall be revised or applied in a manner that renders it lawful and enforceable to the fullest extent possible under law. 
 (d) This Agreement shall inure to the benefit of and shall be binding upon the parties hereto and their respective heirs, legal representatives, successors, and assigns. 

(e) The headings and captions contained herein are for convenience only and shall not control or affect the meaning or construction of
any provision hereof. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and which together shall constitute one and the same instrument. 

(f) This Agreement constitutes the entire agreement, and supersedes all prior agreements and understandings, oral and written, between
the parties hereto with respect to the subject matter hereof. 
 (g) To the extent not preempted by federal law, this Agreement
shall be governed by, and construed in accordance with, the laws of the state of Delaware, without giving effect to the principles of conflicts of law thereof. 
  

	 	13.	Compliance.  

 It
is understood and agreed upon that at all times Grantee will act in full compliance with the Company’s Code of Conduct, Policies and Procedures, JV Compliance Handbook, MDA Compliance Handbook, Gift Policy and the credentialing process
(collectively, the “Policies”).
 Grantee may not improperly use something of value to attempt to induce or actually
induce, either directly or indirectly, a patient to switch to, or continue to receive, treatment at a Company dialysis center in violation of the Policies. Inducement may include paying a patient, providing gifts, or otherwise providing
something of value to a patient to switch to, or continue to receive treatment at a Company dialysis center. Grantee also may not attempt to induce or actually induce a referral source with something of value to obtain referrals in violation of the
Policies. 
 If Grantee’s conduct, whether related to the Cash Performance Award granted under this Agreement or otherwise,
violates the requirements of the immediately preceding two paragraphs, then Grantee will cease vesting in the Cash Performance Award opportunity granted under this Agreement and be subject to immediate disciplinary action, up to and including
termination. 
 If at any time Grantee has questions or concerns about the Compliance provisions in this Section 13, or
suspects any improper conduct related to this initiative, Grantee should immediately contact his or her supervisor or Team Quest. Grantee also may anonymously and confidentially call the Company’s Compliance Hotline at 1-888-458-5848.

  
 7 

 This Agreement may be considered null and void at the discretion of the Company if a signed
copy is not returned to the People Services Department no later than 120 days from the Grant Date. 
 In
Witness Whereof, the Company and the Grantee have executed this Agreement effective as of the date first written above. 
  

							
	Grantee	 	 	 	Company	 	 
				
	  
	 		 	  
	 	
	Printed Name	 		 	Printed Name	 	
				
	  
	 		 	  
	 	
	Signature	 		 	Signature	 	
				
	  
	 		 	  
	 	
	Title	 		 	Title	 	
				
	  
	 		 	  
	 	
	Division/Department	 		 	Division/Department	 	

  
 8EX-10.79

 Exhibit 10.79 
 AMENDMENT NO. 1 TO SOURCING AND SUPPLY AGREEMENT [DELETED] 
 BETWEEN AMGEN
USA INC. AND DAVITA HEALTHCARE PARTNERS INC. 
  
  

This Amendment No. 1 (“Amendment No. 1”) to Sourcing and Supply Agreement [DELETED] (the “Agreement”) is being made by and
between Amgen USA Inc. (“Amgen”) and DaVita Healthcare Partners Inc. f/k/a DaVita Inc. (“Dialysis Center”) and effective as of January 1, 2013 (the “Amendment No. 1 Effective Date”). 

WHEREAS, Amgen and Dialysis Center have entered into that Agreement, effective on January 1, 2012; and 

WHEREAS, Amgen and Dialysis Center mutually desire to amend the Agreement as stated below. 
 NOW, THEREFORE, in consideration of the premises and of the mutual covenants, representations and warranties set forth herein, the parties agree as follows: 

SECTION 1. Definitions; References. Unless otherwise specifically defined herein, each term used herein which is defined in the Agreement
shall have the meaning assigned to such term in the Agreement. Except as amended and supplemented hereby, all of the terms of the Agreement are incorporated herein by reference, shall remain and continue in full force and effect and are hereby
ratified and confirmed in all respects. 
 SECTION 2. Amendment of the Agreement. As of the Amendment No. 1 Effective Date, all
references to DaVita Inc. in the Agreement shall hereby be changed to DaVita Healthcare Partners Inc. 
 SECTION 3. Amendment of
Section 1.9 of Exhibit A. As of the Amendment No. 1 Effective Date, Section 1.9 of Exhibit A of the Agreement entitled “[DELETED]” shall be amended and restated, as follows: 

 

	1.9	“[DELETED]” shall mean for each [DELETED] of EPOGEN purchased by a Dialysis Center Purchaser under this Agreement in any Quarter, the [DELETED] in
effect on the date of purchase less for such Quarter (i) the Discounts that Dialysis Center is eligible to earn under this Agreement during the applicable Quarter, including the [DELETED] Rebate, the [DELETED] Rebate and the [DELETED]
Rebate as applicable, but excluding the [DELETED] Rebate, (ii) any [DELETED] Rebate earned, and (iii) any other discount, rebate or other price adjustment received by a Dialysis Center Purchaser per [DELETED] of EPOGEN which is included in
the “Best Price” reported in Amgen’s Best Price Submission under Title XIX of the Social Security Act in respect of such EPOGEN purchase. 

 SECTION 4. Amendment of Section 1 of Exhibit A. As of the Amendment No. 1 Effective Date, Section 1 of Exhibit A of the Agreement entitled “Definitions” shall be amended
to add the following “[DELETED] Rebate Definitions”: Section 1.24 “[DELETED] Rebate”, Section 1.25 “[DELETED] Rebate Eligibility”, and Section 1.26 “[DELETED] Rebate Period”, as follows:

 Additional Rebate Definitions 
  

	 	1.24	“[DELETED] Rebate” shall mean, a rebate equal to [DELETED] percent ([DELETED]%) of the Qualified Gross Purchases of EPOGEN during the applicable
Quarter. 

  

	 	1.25	“[DELETED] Rebate Eligibility” shall mean, an Amgen ESA Share of Sales during the applicable Quarter that is equal to or greater than [DELETED] percent
([DELETED]%). 

  

	 	1.26	“[DELETED] Rebate Period” shall mean, the period from January 1, 2013 through December 31, 2013. 

 AMENDMENT NO. 1 TO SOURCING AND SUPPLY AGREEMENT [DELETED] 

BETWEEN AMGEN USA INC. AND DAVITA HEALTHCARE PARTNERS INC. 

 
  
  

SECTION 5. Amendment of Section 1.20 of Exhibit A. As of the Amendment No. 1 Effective Date, the row corresponding to 2013 set forth
in the [DELETED] Table set forth in Section 1.20 of Exhibit A of the Agreement entitled “[DELETED]” shall be revised to be, as follows: 
  

			
	 [DELETED] Table

	 Calendar Year
	  	 [DELETED]

	2013	  	$[DELETED] in the event Dialysis Center earns the [DELETED] Rebate in accordance with the terms and conditions of Section 3.6 of this Exhibit A, otherwise
the [DELETED] shall be $[DELETED].

 SECTION 6. Amendment of Section 3 of Exhibit A. As of the Amendment No. 1 Effective Date,
Section 3 of Exhibit A of the Agreement shall be amended to add Section 3.6 entitled “[DELETED] Rebate”, as follows: 
  

	3.6	[DELETED] Rebate. During the [DELETED] Rebate Period, Dialysis Center shall earn the [DELETED] Rebate for each Quarter provided that Dialysis Center shall
have met the [DELETED] Rebate Eligibility during such Quarter. 

  

	3.6.1	Payment of [DELETED] Rebate. Amgen will pay the [DELETED] Rebate within [DELETED] ([DELETED]) days after the end of the corresponding Quarter, provided Amgen is
in receipt of all Relevant Information in a form reasonably acceptable to Amgen. 

  

	3.6.2	Vesting of [DELETED] Rebate. The [DELETED] Rebate for a given Quarter shall vest on the last day of such Quarter. 

 AMENDMENT NO. 1 TO SOURCING AND SUPPLY AGREEMENT [DELETED] 

BETWEEN AMGEN USA INC. AND DAVITA HEALTHCARE PARTNERS INC. 

 
  
  

SECTION 7. Amendment of Section 4 of Exhibit A. As of the Amendment No. 1 Effective Date, the column corresponding to 2013 of the
Summary of Discounts Table set forth in Section 4 of Exhibit A of the Agreement shall be revised to be, as follows: 
  

					
	 Summary of Discounts Table
	 
	 	  	2013	 
	 Base Invoice Discount
	  	 	[DELETED	]% 
	 Base Rate Rebate
	  	 	[DELETED	]% 
	 [DELETED] Rebate
	  	 	[DELETED	]% 
	 [DELETED] Rebate
	  	 	[DELETED	]% 
	 Total Discount Opportunity
	  	 	[DELETED	]% 

 AMENDMENT NO. 1 TO SOURCING AND SUPPLY AGREEMENT [DELETED] 

BETWEEN AMGEN USA INC. AND DAVITA HEALTHCARE PARTNERS INC. 

 
  
  

The Parties have executed this Amendment No. 1 by their designated representatives set forth below effective as of the Amendment No. 1 Effective
Date. 
  

									
	AMGEN USA INC.	 		 	DAVITA HEALTHCARE PARTNERS INC. F/K/A DAVITA INC.
					
	By: 	 	 /s/ Mark Bubany
	 		 	By: 	 	 /s/ Dennis L. Kogod

					
	Name (print):	 	 Mark Bubany
	 		 	Name (print):	 	 Dennis L. Kogod

					
	Its: 	 	 Executive Director, Contracts & Pricing
	 		 	Its:	 	 Chief Operating Officer

					
	Date: 	 	 12/11/12
	 		 	Date: 	 	 12/10/12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00213-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00213-of-00352.parquet"}]]